Rein Therapeutics, Inc. (RNTX) Operating cash flow 2016–2025
Rein Therapeutics, Inc. (RNTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$19.4MFY2025 · since FY2016: -$15.0M → -$19.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$19.4M | +13.1% |
| FY2024 | -$22.3M | -12.5% |
| FY2023 | -$19.8M | +20.3% |
| FY2022 | -$24.9M | -4.7% |
| FY2021 | -$23.8M | -16.0% |
| FY2020 | -$20.5M | +22.7% |
| FY2019 | -$26.5M | +5.2% |
| FY2018 | -$27.9M | -36.0% |
| FY2017 | -$20.5M | -36.7% |
| FY2016 | -$15.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RNTX financial trends
RNTX RevenueRNTX Net incomeRNTX Net marginRNTX Gross profitRNTX Gross marginRNTX Operating incomeRNTX Operating marginRNTX Free cash flowRNTX Capital expendituresRNTX Return on equityRNTX Stock buybacksRNTX Dividends paidRNTX Total assetsRNTX Total liabilitiesRNTX Shareholders’ equityRNTX overview →